Kopran consolidated net profit declines 48.01% in the March 2025 quarter
15 - May - 2025 12:00 | 21 days ago
Net profit of Kopran declined 48.01% to Rs 9.68 crore in the quarter ended March 2025 as against Rs 18.62 crore during the previous quarter ended March 2024. Sales declined 7.37% to Rs 172.36 crore in the quarter ended March 2025 as against Rs 186.08 crore during the previous quarter ended March 2024.
For the full year,net profit declined 24.35% to Rs 38.55 crore in the year ended March 2025 as against Rs 50.96 crore during the previous year ended March 2024. Sales rose 2.44% to Rs 629.60 crore in the year ended March 2025 as against Rs 614.59 crore during the previous year ended March 2024.
Kopran announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.
Kopran announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.
Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly
28 - Apr - 2025 12:00 | 38 days ago
The United States Food and Drug Administration (USFDA) recently carried out a surveillance inspection at Kopran Research Laboratories, the company?s wholly owned subsidiary. The inspection was conducted at the API manufacturing unit located in Mahad, Maharashtra, between April 21 and April 25, 2025.
In a regulatory filing, Kopran confirmed that the inspection was concluded without any observations.
Kopran is engaged in the business of manufacturing of formulation (finished dosage form). On a consolidated basis, net profit of Kopran declined 34.14% to Rs 10.40 crore while net sales rose 4.61% to Rs 166.24 crore in Q3 December 2024 over Q3 December 2023.
Kopran consolidated net profit declines 48.01% in the March 2025 quarter
15 - May - 2025 12:00 | 21 days ago
Net profit of Kopran declined 48.01% to Rs 9.68 crore in the quarter ended March 2025 as against Rs 18.62 crore during the previous quarter ended March 2024. Sales declined 7.37% to Rs 172.36 crore in the quarter ended March 2025 as against Rs 186.08 crore during the previous quarter ended March 2024.
For the full year,net profit declined 24.35% to Rs 38.55 crore in the year ended March 2025 as against Rs 50.96 crore during the previous year ended March 2024. Sales rose 2.44% to Rs 629.60 crore in the year ended March 2025 as against Rs 614.59 crore during the previous year ended March 2024.
Kopran announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.
Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly
28 - Apr - 2025 12:00 | 38 days ago
The United States Food and Drug Administration (USFDA) recently carried out a surveillance inspection at Kopran Research Laboratories, the company?s wholly owned subsidiary. The inspection was conducted at the API manufacturing unit located in Mahad, Maharashtra, between April 21 and April 25, 2025.
In a regulatory filing, Kopran confirmed that the inspection was concluded without any observations.
Kopran is engaged in the business of manufacturing of formulation (finished dosage form). On a consolidated basis, net profit of Kopran declined 34.14% to Rs 10.40 crore while net sales rose 4.61% to Rs 166.24 crore in Q3 December 2024 over Q3 December 2023.
Kopran consolidated net profit declines 48.01% in the March 2025 quarter
15 - May - 2025 12:00 | 21 days ago
Net profit of Kopran declined 48.01% to Rs 9.68 crore in the quarter ended March 2025 as against Rs 18.62 crore during the previous quarter ended March 2024. Sales declined 7.37% to Rs 172.36 crore in the quarter ended March 2025 as against Rs 186.08 crore during the previous quarter ended March 2024.
For the full year,net profit declined 24.35% to Rs 38.55 crore in the year ended March 2025 as against Rs 50.96 crore during the previous year ended March 2024. Sales rose 2.44% to Rs 629.60 crore in the year ended March 2025 as against Rs 614.59 crore during the previous year ended March 2024.
Kopran announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.
Kopran announced that the Board of Directors of the Company at its meeting held on 15 May 2025, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 30%) , subject to the approval of the shareholders.
Kopran jumps as USFDA inspection at subsidiary's plant concludes smoothly
28 - Apr - 2025 12:00 | 38 days ago
The United States Food and Drug Administration (USFDA) recently carried out a surveillance inspection at Kopran Research Laboratories, the company?s wholly owned subsidiary. The inspection was conducted at the API manufacturing unit located in Mahad, Maharashtra, between April 21 and April 25, 2025.
In a regulatory filing, Kopran confirmed that the inspection was concluded without any observations.
Kopran is engaged in the business of manufacturing of formulation (finished dosage form). On a consolidated basis, net profit of Kopran declined 34.14% to Rs 10.40 crore while net sales rose 4.61% to Rs 166.24 crore in Q3 December 2024 over Q3 December 2023.
